{"ticker": {"uuid": "5c4f0b49-7aef-47c1-99e4-1731f3fba92b", "symbol": "CLRB", "name": "Cellectar Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Cellectar Biosciences (CLRB) Q1 2026 earnings summary", "summary": "Cellectar Biosciences announced positive 12-month data from a phase II-B study for iopofosine I-131 in Waldenstr\u00f6m's macroglobulinemia, supporting accelerated FDA approval plans. The company completed a $140 million financing and initiated a phase I-B trial for triple-negative br", "url": "https://quartr.com/events/cellectar-biosciences-clrb-q1-2026_F9pGPt44", "source_name": "Quartr", "published_at": "2026-07-23T12:40:52", "published_display": "23 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Q4 2025 earnings summary", "summary": "Cellectar Biosciences (CLRB) made significant regulatory and clinical progress in 2025, advancing iopofosine for Waldenstrom's macroglobulinemia while expanding its radiotherapeutic pipeline. The company initiated a Phase 1b study for CLR 125, strengthened its supply chain, and s", "url": "https://quartr.com/events/cellectar-biosciences-inc-clrb-q4-2025_F9pGgKQL", "source_name": "Quartr", "published_at": "2026-07-22T18:39:28", "published_display": "22 Jul 2026 18:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Proxy filing Summary", "summary": "Cellectar Biosciences (CLRB) has scheduled its Annual Meeting for July 7, 2026, to be held virtually, with stockholders of record as of May 19, 2026, eligible to vote. Key proposals include the election of two Class III directors, an increase in shares for the 2021 Stock Incentiv", "url": "https://quartr.com/events/cellectar-biosciences-inc-clrb-proxy-filing_F9pGPFF8", "source_name": "Quartr", "published_at": "2026-07-22T12:12:04", "published_display": "22 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Registration filing Summary", "summary": "Cellectar Biosciences (CLRB), a late-stage clinical biopharmaceutical company, has filed a registration summary detailing its business model, financial performance, and capital allocation. The company, which focuses on developing cancer treatments using a proprietary phospholipid", "url": "https://quartr.com/events/cellectar-biosciences-inc-clrb-registration-filing_F9pGPo9J", "source_name": "Quartr", "published_at": "2026-07-22T12:12:04", "published_display": "22 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia", "summary": "Cellectar BioSciences has published a corporate presentation detailing its phospholipid drug conjugate radiotherapy pipeline, highlighting iopofosine I-131 for Waldenstr\u00f6m macroglobulinemia. The company plans to seek US accelerated approval for iopofosine I-131 in the first half ", "url": "https://www.bitget.com/amp/news/detail/12560605525644", "source_name": "Bitget", "published_at": "2026-07-21T19:10:16", "published_display": "21 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers", "summary": "Cellectar Biosciences announced the publication of results from its Phase 1 dose-escalation study of iopofosine I 131 in combination with low-dose dexamethasone for relapsed/refractory multiple myeloma in the journal *Cancers*. The study showed a favorable safety profile with man", "url": "https://www.sahmcapital.com/news/content/cellectar-biosciences-announces-publication-of-phase-1-study-of-iopofosine-i-131-in-peer-reviewed-journal-cancers-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-17T05:42:19", "published_display": "17 Jul 2026 05:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cellectar publishes phase 1 data on multiple myeloma treatment", "summary": "Cellectar Biosciences Inc. announced positive Phase 1 study results for iopofosine I 131 combined with low-dose dexamethasone in relapsed/refractory multiple myeloma patients. The study showed manageable toxicity, encouraging disease control, and antitumor activity, with an overa", "url": "https://www.investing.com/news/company-news/cellectar-publishes-phase-1-data-on-multiple-myeloma-treatment-93CH-4793057", "source_name": "Investing.com", "published_at": "2026-07-15T12:12:04", "published_display": "15 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Myeloma Data: 84.6% of 26 Evaluable Patients Stable or Better", "summary": "Cellectar Biosciences announced the publication of Phase 1 study results for iopofosine I 131 with low-dose dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients in the peer-reviewed journal Cancers. The study showed that 84.6% of 26 evaluable patients", "url": "https://www.stocktitan.net/news/CLRB/cellectar-biosciences-announces-publication-of-phase-1-study-of-xauk8j9dg94t.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:12:15", "published_display": "15 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxONHZfMzRVZld5aTlQbl9UV2ZZUjNtckx2YzlCNUstLTV2ZkJfNkRkQVlLODBDVGdvYVNkaEtWOGJfbHFPVFIyak4wYVhTUENtM3owNmxiNldfR1ZjRmJLcll1T2hNT2Itd0pCRVhJZlhSaG5nUGlDWng5dlJTWXk4X1Bad0llb3FfVnNIMHhEZVRJdjRpQmZrOEhISmtoWTQ?oc=5", "source_name": "Market source", "published_at": "2026-07-11T07:00:00+00:00", "published_display": "11 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences, Inc. Files Form 8-K: Updated Stock Incentive Plan and Corporate Details for 2026", "summary": "Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced key developments from its 2026 Annual Meeting of Stockholders, including the approval of a material amendment to its 2021 Stock Incentive Plan, increasing shares reserved for issuance by 2,000,000. Shareholders also approved ex", "url": "https://www.minichart.com.sg/2026/07/11/cellectar-biosciences-inc-files-form-8-k-updated-stock-incentive-plan-and-corporate-details-for-2026/", "source_name": "Minichart", "published_at": "2026-07-11T01:20:07", "published_display": "11 Jul 2026 01:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cellectar Biosciences Inc For: 10 July By Investing.com", "summary": "This article reports on a Form 4 filing for Cellectar Biosciences Inc (CLRB) on July 10, 2026. Form 4 filings disclose transactions by company insiders, indicating purchases or sales of company stock. The article provides the company name and filing date but no further details on", "url": "https://ca.investing.com/news/stock-market-news/form-4-cellectar-biosciences-inc-for-10-july-93CH-4730027", "source_name": "Investing.com Canada", "published_at": "2026-07-11T01:09:07", "published_display": "11 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (NASDAQ: CLRB) awards 15,000 stock options to consultant", "summary": "Cellectar Biosciences (NASDAQ: CLRB) has awarded 15,000 stock options to consultant Loren Stefan. These options have an exercise price of $2.6900 per share and will expire on July 8, 2036. The award vests in full on July 8, 2027, provided Stefan continues his service until that d", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-a-cellectar-biosciences-inc-amended-insider-trading-activity-2253719cc2ff.html", "source_name": "Stock Titan", "published_at": "2026-07-11T01:06:07", "published_display": "11 Jul 2026 01:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (NASDAQ: CLRB) holders approve more stock awards and large warrant exercise", "summary": "Cellectar Biosciences (NASDAQ: CLRB) stockholders approved several key proposals at their 2026 Annual Meeting, including the election of Class III directors, an increase of 2,000,000 shares for their 2021 Stock Incentive Plan, and the ratification of Deloitte & Touche LLP as thei", "url": "https://www.stocktitan.net/sec-filings/CLRB/8-k-cellectar-biosciences-inc-reports-material-event-e94e7e1ec1ea.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:40:07", "published_display": "10 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar (CLRB) director receives 25,000 stock options at $2.70 strike", "summary": "Cellectar Biosciences director Frederick W. Driscoll was granted 25,000 stock options with an exercise price of $2.70 per share. These options will vest in full on July 7, 2027, subject to his continued service, and are set to expire on July 7, 2036. This transaction increased hi", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-cfb1480f47c7.html", "source_name": "Stock Titan", "published_at": "2026-07-09T13:39:28", "published_display": "09 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) director awarded 25,000 options at $2.70 strike", "summary": "Cellectar Biosciences director John Neis was granted 25,000 stock options with an exercise price of $2.70 per share, expiring on July 7, 2036. The options will fully vest on July 7, 2027, provided Neis continues his service to the company. This constitutes a compensation award ra", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-0824917d329e.html", "source_name": "Stock Titan", "published_at": "2026-07-09T02:12:19", "published_display": "09 Jul 2026 02:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar (CLRB) awards director Andrew Gu 25,000 options", "summary": "Cellectar Biosciences director Andrew Gu was granted 25,000 stock options as equity compensation on July 7, 2026. These options have an exercise price of $2.70 per share and an expiration date of July 7, 2036. The options will fully vest on July 7, 2027, provided he continues his", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-4f9cd490f1e0.html", "source_name": "Stock Titan", "published_at": "2026-07-09T02:12:19", "published_display": "09 Jul 2026 02:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) director receives grant of 25,000 stock options", "summary": "Cellectar Biosciences director Asher Chanan-Khan was granted 25,000 stock options with an exercise price of $2.70 per share, expiring on July 7, 2036. The options will vest in full on July 7, 2027, contingent on his continued service to the company. This transaction is classified", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-b97b29092759.html", "source_name": "Stock Titan", "published_at": "2026-07-09T02:10:09", "published_display": "09 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar (CLRB) CFO awarded 92,000 stock options at $3.14 strike price", "summary": "Cellectar Biosciences CFO Chad J. Kolean has been awarded 92,000 stock options with a strike price of $3.14 per share, contingent on stockholder approval of the amended 2021 Stock Incentive Plan, which occurred on July 7, 2026. These options will vest over a three-year period, wi", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-17a87a3b2138.html", "source_name": "Stock Titan", "published_at": "2026-07-09T02:10:09", "published_display": "09 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cellectar Biosciences Inc For: 8 July By Investing.com", "summary": "This article provides a Form 4 filing for Cellectar Biosciences Inc (CLRB) on July 8. It indicates a minor positive change in the stock price (+0.18%) and was published by Investing.com. The content primarily serves as an announcement for the regulatory filing.", "url": "https://ng.investing.com/news/stock-market-news/form-4-cellectar-biosciences-inc-for-8-july-93CH-2592108", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T02:08:00", "published_display": "09 Jul 2026 02:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) CEO awarded 250,000 stock options", "summary": "Cellectar Biosciences' President & CEO, James V. Caruso, was granted 250,000 stock options at an exercise price of $3.14 per share. This grant was contingent on stockholder approval of the amended 2021 Stock Incentive Plan, which occurred on July 7, 2026. The options will vest ov", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-6ff6d5964a30.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:41:54", "published_display": "09 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) director granted 37,500 stock options", "summary": "Douglas J. Swirsky, a director at Cellectar Biosciences (CLRB), was granted 37,500 stock options with an exercise price of $2.70 per share. These options are a compensation award, not an open-market transaction, and will fully vest on July 7, 2027, provided he continues his servi", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-4a7bea0da66b.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:41:54", "published_display": "09 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Consultant for Cellectar (NASDAQ: CLRB) receives grant of 15,000 stock options", "summary": "Cellectar Biosciences, Inc. consultant Loren Stefan was granted 15,000 stock options with an exercise price of $2.68 per share, which will vest fully on July 8, 2027, provided continued service. These options expire on July 8, 2036. This transaction is an insider grant, not a mar", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-6d4fc29cb62b.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:04:31", "published_display": "09 Jul 2026 01:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) grants COO 118,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZFNVanJZNGRGUnVCc0hmV0VhY0ZBQ0FpTEVoN2hJamlueHh4T0s1bnJPQ1ZjQU5jT3ZrWWlvUEpyVXRKOVVMbGJDZnlPX1Z4R1FzbXgxQVBwUU16T3FlckVEVk9iZkxBb2VlZjNzOUZCellYUER6bHJQZGdzOUpoUWFlMEg0em9hM1Z3RWJGQWhJTkJsZmxiMXBzSVFIdGV2NkdpUjdsT0lGVWVRVXVkN3lkYlpZZmRPemJv?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLRB - Cellectar Biosciences Inc Options", "summary": "This article provides a detailed financial overview of Cellectar Biosciences Inc (CLRB), including its last closing price, dollar and percentage changes, and various financial metrics such as market cap, income, sales, and employee count. It also covers performance indicators lik", "url": "https://finviz.com/stock?t=CLRB&p=d&ty=oc&b=1&r=m1", "source_name": "Finviz", "published_at": "2026-07-03T11:40:20", "published_display": "03 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Cellectar Biosciences, Inc. \u2013 NASDAQ:CLRB", "summary": "The document displays the enterprise value to EBIT forward for Cellectar Biosciences, Inc. (NASDAQ: CLRB) on TradingView. It provides market data, financial figures, and other company-specific information.", "url": "https://www.tradingview.com/symbols/NASDAQ-CLRB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T16:10:45", "published_display": "26 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janus Henderson Group holds 9.99% of Cellectar Biosciences (CLRB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxORnpLWENSY1Qycl9IbjJpMVh3X2IwRTMwTHBteTR3THRFZFd0ak9nRnFhb1dWcmNFaldfd21DZTRSdUhDaUVfaEdmU0Y2MllQaTdtdGtUVnlWRjhYRG5XTGlhNGt5d3gxYTczZnk4em5pQXVxQ0t1dVVVQ1p1bF9nc1RMR25TZUZDRy1VX2RzWEppNkZOeVoyUkRvQVRTaS16cVlZS0djMC1fTTRNX3ZlVGo3bEdZcVFybWZCb3A1a2dLMEx4OHBYV2tyVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Cellectar Biosciences, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQWEQwbEpKaWJUVFU4Q0VHTURrMlY3NWladEk1dXZvQ0poLVMyTzhoa2xEajdKbkd3WFRMWVMtUUdiMVhRVG14V282dm5Bd21sUXRGTlZOVGxlSHFpNzh0X3loZVJyOGJkZEE0SDlKN1JJVlh1Q2hGdFEyblFWSkYyODdmWUEtd0NCdUpfWHd2akZ4RGM5S2VxWXB2RUlweG1aQTVER2xjVjU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenstr\u00f6m Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cellectar-biosciences-highlight-compelling-efficacy-120500330.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:05:00+00:00", "published_display": "01 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences Files for Secondary Offering of Common Shares", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cellectar-biosciences-files-secondary-offering-212450495.html", "source_name": "MT Newswires", "published_at": "2026-05-19T21:24:50+00:00", "published_display": "19 May 2026 21:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cellectar-biosciences-inc-clrb-q1-230208751.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T23:02:08+00:00", "published_display": "14 May 2026 23:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/a0cf560d-fb39-336c-a681-89a129556c74/cellectar-biosciences%2C-inc..html", "source_name": "Moby", "published_at": "2026-05-14T21:08:53+00:00", "published_display": "14 May 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar (CLRB) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/32db488a-020f-3add-a430-faf2cc2b89ba/cellectar-%28clrb%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-14T18:49:13+00:00", "published_display": "14 May 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cellectar-biosciences-reports-first-quarter-111500091.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:15:00+00:00", "published_display": "14 May 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cellectar-biosciences-report-first-quarter-120500314.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T12:05:00+00:00", "published_display": "11 May 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOM2I0dXk1WFN1UnBWMWZiOG9heFdRQnUwWE9lSGY1S0d0UENXREZrcnVpTHhJbEpEZnZ4TDBGQXJhVlpHTnNGbk53X1hnRkZCWFBfYlFBNGp4S2VGNEh6c0hWTm9VUXZPUXV6bjc4SHE0UXpEQlBjd2lYVnFrRE9vXzRtYjNOZzdRbEFEQW93ZjkzYXJBc2ViclBRZGsxNWw5VjR4YUk0UQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Cellectar Biosciences (CLRB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5TU01Fb3g5VXozNnRuU3h5RDItcl9VeTg5OUVvVTRQYmxKSkJPS21TZDhfVDBOQmg5RTdpdmp5TTNKZjBGRFpQSW9heGtkYmRqUlE4dlZPZlpTeHR1X2Z2a2liRk1oMmdCM1JEZQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLRB Stock Surged 27% Today \u2013 Here\u2019s Why Retail Is Bullish About Cellectar\u2019s Blood Cancer Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdEhZWmxKUEx4TTVZSkU0bTlIVnN1bWJTT0p1WHhPOGMwRmhGYVpUMlpXVkI0Y25kYlQyQ3RXZ3RVRXpPbU9LNHZXWEVmM09jUVR0YlRGcy1kSVY1TlVUZ0JWNU8yZkg3OXJ6aVJjSl9Mb0ZNTkVSUUpNOXU0aUNFN2hNVVVIMkUweFBQSUFSelBLZGJIamR4OFZWbEFtTnVodXJGQ25lWmZDX29zb0E?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOcm1VWG1RdmV6OGJjNWU5bnZLTG0xVXFMQk9hSVpDLTZYZUdCNFBGTWlHdjNNNWx2VW80R0tTeG9MY0VPNjgwVW5FeEZ3U1hYLWQ0VUp1ejRxbXdET004RExJSTFUZ1JMeWJiLU94OTg0RmZjVVJZdElNWWUzQzNBNV9mdXpNaGtsX1E5NEJkR0daZVkycVhqRWRyUHdYUDNDSUFhbEVzbE1QRTVlbF9qS3IyWmpGVXA2STVHQXdNeFV6ZEFuRDAxVHN2RmFnbzVlRnlkNXpLOEdLVE14QlBWb240d3Q?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar lines up $140M to fund cancer drug study and FDA filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMHl3V3ctOFZuOHJMT3BkM2p1T2JiUEdyWjh1c0tmQTNSa0ZrQkJGVTRNdEVlTjN2TVNnM1ZsVHUwWXhOSWtxUjBBM0poQlJoVmdiSUpuQU9vV1ZZTDVULWt4bmRHcUtzMnpTNXBBS19NRFlRc21JUmdfQ0FtTEtUWkU0Um9vWWQ4NWNQNWNhZHpkSVZ3S2VDSGRrS0o2czYwZmhKUmptcVhaZzVYemE3SlV6NlZqNVBmTThlMXFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences stock soars 130% on $140M financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQRktwVjlNRTN0b29rbmdOenBwM0ZnVjNITzJ1LTYwbWhBb2dVajhEUmN5VHc4eGFjSS0wSlF1ODdRdndXRU5TUnhtTms1Z1RuVnlFSmQ1NFRUaU1DaWFFYl80ZDlvUF84alJaT01hRDl2bTd4VWVpS1ZOcnpEd2hiZ091Q0g4bkpIOUdIWkZtdHVvYk1DQkpoVkJfejJwTF9FcTBGY1EwQUM1UDRqYjhEV2JtRDhKVUVD?oc=5", "source_name": "Investing.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "First patient joins Cellectar study for hard-to-treat breast cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPRTdJODlZQTMyV1BOZVRia3BGcGpwcjg0ZUpYaVA5eFRsTDc3aHBwbElSTnFQT1o2RGYtWmVaZUxheDk5aEk3T0Y5QVlRVjJENXpGZUZLUERYY00zRl9uUlVnYkRXV0tmWlBjR0N5SzNlanJ3Y3pVNnVJYXUtSTdRWmxIM3JYOG5sUWpMTm1JVzJiOHEwUnBJWVhkVHpJVFR3czZrY1V2YzJLV09TSERsTVRB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cellectar Biosciences, Inc. Completes $6.9 Million Public Offering to Advance Cancer Treatment Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOdWNNTWU2dFlSMTJIRldEbnlXNWYwUU96T1k0NmVid2RoajhBM1pRTm10azNVSFRRLTRsR2ZlMkpHSHlSU3dTb3EzQ09td0lvd2NIMVR6ek5aVVhBRHBhNFJfWWJnRkg2YVZZeUdMc0wyOUtzMXJQN2xoZXBzRGpPS0MwZGM4RXIxQ3padVVsdzhsUGlpYTVnTV9qbEdPVUVYZVdyd1M0STNlQjBoZ1JkcEhEejEtaDNEM1p1b3pSNVdfXy0zUUFPbUQ5dzdqa05vSVAxekJHV0Frdk0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-07-02T07:00:00+00:00", "published_display": "02 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBUYURuODFFOEhsWFA4dGYwRXRza0pMMzRVblBKV1I5WUlmZlpicGx1aVZSSXFKMXRjNm1YY2x5OWdLZnpLZ2xHRnZMU3NtQQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-03T18:39:16+00:00", "published_display": "03 Sep 2020 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Stock Price, News & Analysis $CLRB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5Gcm5MeURYNEVqdzA4YXBHSThyTkNXMmxTMlZqUmx4UElTbC15NmxKZURkU1h1YzdxeWZfRHZTVm5qN3lNWmxNVVQxYkg1V2Q2TldGUHVFUWthUQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-12T06:12:10+00:00", "published_display": "12 Aug 2016 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cellectar Biosciences (CLRB) Q1 2026 earnings summary", "summary": "Cellectar Biosciences announced positive 12-month data from a phase II-B study for iopofosine I-131 in Waldenstr\u00f6m's macroglobulinemia, supporting accelerated FDA approval plans. The company completed a $140 million financing and initiated a phase I-B trial for triple-negative br", "url": "https://quartr.com/events/cellectar-biosciences-clrb-q1-2026_F9pGPt44", "source_name": "Quartr", "published_at": "2026-07-23T12:40:52", "published_display": "23 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Q4 2025 earnings summary", "summary": "Cellectar Biosciences (CLRB) made significant regulatory and clinical progress in 2025, advancing iopofosine for Waldenstrom's macroglobulinemia while expanding its radiotherapeutic pipeline. The company initiated a Phase 1b study for CLR 125, strengthened its supply chain, and s", "url": "https://quartr.com/events/cellectar-biosciences-inc-clrb-q4-2025_F9pGgKQL", "source_name": "Quartr", "published_at": "2026-07-22T18:39:28", "published_display": "22 Jul 2026 18:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Proxy filing Summary", "summary": "Cellectar Biosciences (CLRB) has scheduled its Annual Meeting for July 7, 2026, to be held virtually, with stockholders of record as of May 19, 2026, eligible to vote. Key proposals include the election of two Class III directors, an increase in shares for the 2021 Stock Incentiv", "url": "https://quartr.com/events/cellectar-biosciences-inc-clrb-proxy-filing_F9pGPFF8", "source_name": "Quartr", "published_at": "2026-07-22T12:12:04", "published_display": "22 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Registration filing Summary", "summary": "Cellectar Biosciences (CLRB), a late-stage clinical biopharmaceutical company, has filed a registration summary detailing its business model, financial performance, and capital allocation. The company, which focuses on developing cancer treatments using a proprietary phospholipid", "url": "https://quartr.com/events/cellectar-biosciences-inc-clrb-registration-filing_F9pGPo9J", "source_name": "Quartr", "published_at": "2026-07-22T12:12:04", "published_display": "22 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia", "summary": "Cellectar BioSciences has published a corporate presentation detailing its phospholipid drug conjugate radiotherapy pipeline, highlighting iopofosine I-131 for Waldenstr\u00f6m macroglobulinemia. The company plans to seek US accelerated approval for iopofosine I-131 in the first half ", "url": "https://www.bitget.com/amp/news/detail/12560605525644", "source_name": "Bitget", "published_at": "2026-07-21T19:10:16", "published_display": "21 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers", "summary": "Cellectar Biosciences announced the publication of results from its Phase 1 dose-escalation study of iopofosine I 131 in combination with low-dose dexamethasone for relapsed/refractory multiple myeloma in the journal *Cancers*. The study showed a favorable safety profile with man", "url": "https://www.sahmcapital.com/news/content/cellectar-biosciences-announces-publication-of-phase-1-study-of-iopofosine-i-131-in-peer-reviewed-journal-cancers-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-17T05:42:19", "published_display": "17 Jul 2026 05:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar publishes phase 1 data on multiple myeloma treatment", "summary": "Cellectar Biosciences Inc. announced positive Phase 1 study results for iopofosine I 131 combined with low-dose dexamethasone in relapsed/refractory multiple myeloma patients. The study showed manageable toxicity, encouraging disease control, and antitumor activity, with an overa", "url": "https://www.investing.com/news/company-news/cellectar-publishes-phase-1-data-on-multiple-myeloma-treatment-93CH-4793057", "source_name": "Investing.com", "published_at": "2026-07-15T12:12:04", "published_display": "15 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Myeloma Data: 84.6% of 26 Evaluable Patients Stable or Better", "summary": "Cellectar Biosciences announced the publication of Phase 1 study results for iopofosine I 131 with low-dose dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients in the peer-reviewed journal Cancers. The study showed that 84.6% of 26 evaluable patients", "url": "https://www.stocktitan.net/news/CLRB/cellectar-biosciences-announces-publication-of-phase-1-study-of-xauk8j9dg94t.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:12:15", "published_display": "15 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxONHZfMzRVZld5aTlQbl9UV2ZZUjNtckx2YzlCNUstLTV2ZkJfNkRkQVlLODBDVGdvYVNkaEtWOGJfbHFPVFIyak4wYVhTUENtM3owNmxiNldfR1ZjRmJLcll1T2hNT2Itd0pCRVhJZlhSaG5nUGlDWng5dlJTWXk4X1Bad0llb3FfVnNIMHhEZVRJdjRpQmZrOEhISmtoWTQ?oc=5", "source_name": "Market source", "published_at": "2026-07-11T07:00:00+00:00", "published_display": "11 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences, Inc. Files Form 8-K: Updated Stock Incentive Plan and Corporate Details for 2026", "summary": "Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced key developments from its 2026 Annual Meeting of Stockholders, including the approval of a material amendment to its 2021 Stock Incentive Plan, increasing shares reserved for issuance by 2,000,000. Shareholders also approved ex", "url": "https://www.minichart.com.sg/2026/07/11/cellectar-biosciences-inc-files-form-8-k-updated-stock-incentive-plan-and-corporate-details-for-2026/", "source_name": "Minichart", "published_at": "2026-07-11T01:20:07", "published_display": "11 Jul 2026 01:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cellectar Biosciences Inc For: 10 July By Investing.com", "summary": "This article reports on a Form 4 filing for Cellectar Biosciences Inc (CLRB) on July 10, 2026. Form 4 filings disclose transactions by company insiders, indicating purchases or sales of company stock. The article provides the company name and filing date but no further details on", "url": "https://ca.investing.com/news/stock-market-news/form-4-cellectar-biosciences-inc-for-10-july-93CH-4730027", "source_name": "Investing.com Canada", "published_at": "2026-07-11T01:09:07", "published_display": "11 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (NASDAQ: CLRB) awards 15,000 stock options to consultant", "summary": "Cellectar Biosciences (NASDAQ: CLRB) has awarded 15,000 stock options to consultant Loren Stefan. These options have an exercise price of $2.6900 per share and will expire on July 8, 2036. The award vests in full on July 8, 2027, provided Stefan continues his service until that d", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-a-cellectar-biosciences-inc-amended-insider-trading-activity-2253719cc2ff.html", "source_name": "Stock Titan", "published_at": "2026-07-11T01:06:07", "published_display": "11 Jul 2026 01:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (NASDAQ: CLRB) holders approve more stock awards and large warrant exercise", "summary": "Cellectar Biosciences (NASDAQ: CLRB) stockholders approved several key proposals at their 2026 Annual Meeting, including the election of Class III directors, an increase of 2,000,000 shares for their 2021 Stock Incentive Plan, and the ratification of Deloitte & Touche LLP as thei", "url": "https://www.stocktitan.net/sec-filings/CLRB/8-k-cellectar-biosciences-inc-reports-material-event-e94e7e1ec1ea.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:40:07", "published_display": "10 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar (CLRB) director receives 25,000 stock options at $2.70 strike", "summary": "Cellectar Biosciences director Frederick W. Driscoll was granted 25,000 stock options with an exercise price of $2.70 per share. These options will vest in full on July 7, 2027, subject to his continued service, and are set to expire on July 7, 2036. This transaction increased hi", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-cfb1480f47c7.html", "source_name": "Stock Titan", "published_at": "2026-07-09T13:39:28", "published_display": "09 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) director awarded 25,000 options at $2.70 strike", "summary": "Cellectar Biosciences director John Neis was granted 25,000 stock options with an exercise price of $2.70 per share, expiring on July 7, 2036. The options will fully vest on July 7, 2027, provided Neis continues his service to the company. This constitutes a compensation award ra", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-0824917d329e.html", "source_name": "Stock Titan", "published_at": "2026-07-09T02:12:19", "published_display": "09 Jul 2026 02:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar (CLRB) awards director Andrew Gu 25,000 options", "summary": "Cellectar Biosciences director Andrew Gu was granted 25,000 stock options as equity compensation on July 7, 2026. These options have an exercise price of $2.70 per share and an expiration date of July 7, 2036. The options will fully vest on July 7, 2027, provided he continues his", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-4f9cd490f1e0.html", "source_name": "Stock Titan", "published_at": "2026-07-09T02:12:19", "published_display": "09 Jul 2026 02:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) director receives grant of 25,000 stock options", "summary": "Cellectar Biosciences director Asher Chanan-Khan was granted 25,000 stock options with an exercise price of $2.70 per share, expiring on July 7, 2036. The options will vest in full on July 7, 2027, contingent on his continued service to the company. This transaction is classified", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-b97b29092759.html", "source_name": "Stock Titan", "published_at": "2026-07-09T02:10:09", "published_display": "09 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar (CLRB) CFO awarded 92,000 stock options at $3.14 strike price", "summary": "Cellectar Biosciences CFO Chad J. Kolean has been awarded 92,000 stock options with a strike price of $3.14 per share, contingent on stockholder approval of the amended 2021 Stock Incentive Plan, which occurred on July 7, 2026. These options will vest over a three-year period, wi", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-17a87a3b2138.html", "source_name": "Stock Titan", "published_at": "2026-07-09T02:10:09", "published_display": "09 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cellectar Biosciences Inc For: 8 July By Investing.com", "summary": "This article provides a Form 4 filing for Cellectar Biosciences Inc (CLRB) on July 8. It indicates a minor positive change in the stock price (+0.18%) and was published by Investing.com. The content primarily serves as an announcement for the regulatory filing.", "url": "https://ng.investing.com/news/stock-market-news/form-4-cellectar-biosciences-inc-for-8-july-93CH-2592108", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T02:08:00", "published_display": "09 Jul 2026 02:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) CEO awarded 250,000 stock options", "summary": "Cellectar Biosciences' President & CEO, James V. Caruso, was granted 250,000 stock options at an exercise price of $3.14 per share. This grant was contingent on stockholder approval of the amended 2021 Stock Incentive Plan, which occurred on July 7, 2026. The options will vest ov", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-6ff6d5964a30.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:41:54", "published_display": "09 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) director granted 37,500 stock options", "summary": "Douglas J. Swirsky, a director at Cellectar Biosciences (CLRB), was granted 37,500 stock options with an exercise price of $2.70 per share. These options are a compensation award, not an open-market transaction, and will fully vest on July 7, 2027, provided he continues his servi", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-4a7bea0da66b.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:41:54", "published_display": "09 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Consultant for Cellectar (NASDAQ: CLRB) receives grant of 15,000 stock options", "summary": "Cellectar Biosciences, Inc. consultant Loren Stefan was granted 15,000 stock options with an exercise price of $2.68 per share, which will vest fully on July 8, 2027, provided continued service. These options expire on July 8, 2036. This transaction is an insider grant, not a mar", "url": "https://www.stocktitan.net/sec-filings/CLRB/form-4-cellectar-biosciences-inc-insider-trading-activity-6d4fc29cb62b.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:04:31", "published_display": "09 Jul 2026 01:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) grants COO 118,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZFNVanJZNGRGUnVCc0hmV0VhY0ZBQ0FpTEVoN2hJamlueHh4T0s1bnJPQ1ZjQU5jT3ZrWWlvUEpyVXRKOVVMbGJDZnlPX1Z4R1FzbXgxQVBwUU16T3FlckVEVk9iZkxBb2VlZjNzOUZCellYUER6bHJQZGdzOUpoUWFlMEg0em9hM1Z3RWJGQWhJTkJsZmxiMXBzSVFIdGV2NkdpUjdsT0lGVWVRVXVkN3lkYlpZZmRPemJv?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLRB - Cellectar Biosciences Inc Options", "summary": "This article provides a detailed financial overview of Cellectar Biosciences Inc (CLRB), including its last closing price, dollar and percentage changes, and various financial metrics such as market cap, income, sales, and employee count. It also covers performance indicators lik", "url": "https://finviz.com/stock?t=CLRB&p=d&ty=oc&b=1&r=m1", "source_name": "Finviz", "published_at": "2026-07-03T11:40:20", "published_display": "03 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Cellectar Biosciences, Inc. \u2013 NASDAQ:CLRB", "summary": "The document displays the enterprise value to EBIT forward for Cellectar Biosciences, Inc. (NASDAQ: CLRB) on TradingView. It provides market data, financial figures, and other company-specific information.", "url": "https://www.tradingview.com/symbols/NASDAQ-CLRB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T16:10:45", "published_display": "26 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janus Henderson Group holds 9.99% of Cellectar Biosciences (CLRB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxORnpLWENSY1Qycl9IbjJpMVh3X2IwRTMwTHBteTR3THRFZFd0ak9nRnFhb1dWcmNFaldfd21DZTRSdUhDaUVfaEdmU0Y2MllQaTdtdGtUVnlWRjhYRG5XTGlhNGt5d3gxYTczZnk4em5pQXVxQ0t1dVVVQ1p1bF9nc1RMR25TZUZDRy1VX2RzWEppNkZOeVoyUkRvQVRTaS16cVlZS0djMC1fTTRNX3ZlVGo3bEdZcVFybWZCb3A1a2dLMEx4OHBYV2tyVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Cellectar Biosciences, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQWEQwbEpKaWJUVFU4Q0VHTURrMlY3NWladEk1dXZvQ0poLVMyTzhoa2xEajdKbkd3WFRMWVMtUUdiMVhRVG14V282dm5Bd21sUXRGTlZOVGxlSHFpNzh0X3loZVJyOGJkZEE0SDlKN1JJVlh1Q2hGdFEyblFWSkYyODdmWUEtd0NCdUpfWHd2akZ4RGM5S2VxWXB2RUlweG1aQTVER2xjVjU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenstr\u00f6m Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cellectar-biosciences-highlight-compelling-efficacy-120500330.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:05:00+00:00", "published_display": "01 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences Files for Secondary Offering of Common Shares", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cellectar-biosciences-files-secondary-offering-212450495.html", "source_name": "MT Newswires", "published_at": "2026-05-19T21:24:50+00:00", "published_display": "19 May 2026 21:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cellectar-biosciences-inc-clrb-q1-230208751.html", "source_name": "GuruFocus.com", "published_at": "2026-05-14T23:02:08+00:00", "published_display": "14 May 2026 23:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/a0cf560d-fb39-336c-a681-89a129556c74/cellectar-biosciences%2C-inc..html", "source_name": "Moby", "published_at": "2026-05-14T21:08:53+00:00", "published_display": "14 May 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar (CLRB) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/32db488a-020f-3add-a430-faf2cc2b89ba/cellectar-%28clrb%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-14T18:49:13+00:00", "published_display": "14 May 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cellectar-biosciences-reports-first-quarter-111500091.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:15:00+00:00", "published_display": "14 May 2026 11:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cellectar-biosciences-report-first-quarter-120500314.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T12:05:00+00:00", "published_display": "11 May 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOM2I0dXk1WFN1UnBWMWZiOG9heFdRQnUwWE9lSGY1S0d0UENXREZrcnVpTHhJbEpEZnZ4TDBGQXJhVlpHTnNGbk53X1hnRkZCWFBfYlFBNGp4S2VGNEh6c0hWTm9VUXZPUXV6bjc4SHE0UXpEQlBjd2lYVnFrRE9vXzRtYjNOZzdRbEFEQW93ZjkzYXJBc2ViclBRZGsxNWw5VjR4YUk0UQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Cellectar Biosciences (CLRB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5TU01Fb3g5VXozNnRuU3h5RDItcl9VeTg5OUVvVTRQYmxKSkJPS21TZDhfVDBOQmg5RTdpdmp5TTNKZjBGRFpQSW9heGtkYmRqUlE4dlZPZlpTeHR1X2Z2a2liRk1oMmdCM1JEZQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CLRB Stock Surged 27% Today \u2013 Here\u2019s Why Retail Is Bullish About Cellectar\u2019s Blood Cancer Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdEhZWmxKUEx4TTVZSkU0bTlIVnN1bWJTT0p1WHhPOGMwRmhGYVpUMlpXVkI0Y25kYlQyQ3RXZ3RVRXpPbU9LNHZXWEVmM09jUVR0YlRGcy1kSVY1TlVUZ0JWNU8yZkg3OXJ6aVJjSl9Mb0ZNTkVSUUpNOXU0aUNFN2hNVVVIMkUweFBQSUFSelBLZGJIamR4OFZWbEFtTnVodXJGQ25lWmZDX29zb0E?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOcm1VWG1RdmV6OGJjNWU5bnZLTG0xVXFMQk9hSVpDLTZYZUdCNFBGTWlHdjNNNWx2VW80R0tTeG9MY0VPNjgwVW5FeEZ3U1hYLWQ0VUp1ejRxbXdET004RExJSTFUZ1JMeWJiLU94OTg0RmZjVVJZdElNWWUzQzNBNV9mdXpNaGtsX1E5NEJkR0daZVkycVhqRWRyUHdYUDNDSUFhbEVzbE1QRTVlbF9qS3IyWmpGVXA2STVHQXdNeFV6ZEFuRDAxVHN2RmFnbzVlRnlkNXpLOEdLVE14QlBWb240d3Q?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar lines up $140M to fund cancer drug study and FDA filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMHl3V3ctOFZuOHJMT3BkM2p1T2JiUEdyWjh1c0tmQTNSa0ZrQkJGVTRNdEVlTjN2TVNnM1ZsVHUwWXhOSWtxUjBBM0poQlJoVmdiSUpuQU9vV1ZZTDVULWt4bmRHcUtzMnpTNXBBS19NRFlRc21JUmdfQ0FtTEtUWkU0Um9vWWQ4NWNQNWNhZHpkSVZ3S2VDSGRrS0o2czYwZmhKUmptcVhaZzVYemE3SlV6NlZqNVBmTThlMXFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences stock soars 130% on $140M financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQRktwVjlNRTN0b29rbmdOenBwM0ZnVjNITzJ1LTYwbWhBb2dVajhEUmN5VHc4eGFjSS0wSlF1ODdRdndXRU5TUnhtTms1Z1RuVnlFSmQ1NFRUaU1DaWFFYl80ZDlvUF84alJaT01hRDl2bTd4VWVpS1ZOcnpEd2hiZ091Q0g4bkpIOUdIWkZtdHVvYk1DQkpoVkJfejJwTF9FcTBGY1EwQUM1UDRqYjhEV2JtRDhKVUVD?oc=5", "source_name": "Investing.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First patient joins Cellectar study for hard-to-treat breast cancer", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPRTdJODlZQTMyV1BOZVRia3BGcGpwcjg0ZUpYaVA5eFRsTDc3aHBwbElSTnFQT1o2RGYtWmVaZUxheDk5aEk3T0Y5QVlRVjJENXpGZUZLUERYY00zRl9uUlVnYkRXV0tmWlBjR0N5SzNlanJ3Y3pVNnVJYXUtSTdRWmxIM3JYOG5sUWpMTm1JVzJiOHEwUnBJWVhkVHpJVFR3czZrY1V2YzJLV09TSERsTVRB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences, Inc. Completes $6.9 Million Public Offering to Advance Cancer Treatment Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxOdWNNTWU2dFlSMTJIRldEbnlXNWYwUU96T1k0NmVid2RoajhBM1pRTm10azNVSFRRLTRsR2ZlMkpHSHlSU3dTb3EzQ09td0lvd2NIMVR6ek5aVVhBRHBhNFJfWWJnRkg2YVZZeUdMc0wyOUtzMXJQN2xoZXBzRGpPS0MwZGM4RXIxQ3padVVsdzhsUGlpYTVnTV9qbEdPVUVYZVdyd1M0STNlQjBoZ1JkcEhEejEtaDNEM1p1b3pSNVdfXy0zUUFPbUQ5dzdqa05vSVAxekJHV0Frdk0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-07-02T07:00:00+00:00", "published_display": "02 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBUYURuODFFOEhsWFA4dGYwRXRza0pMMzRVblBKV1I5WUlmZlpicGx1aVZSSXFKMXRjNm1YY2x5OWdLZnpLZ2xHRnZMU3NtQQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-09-03T18:39:16+00:00", "published_display": "03 Sep 2020 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cellectar Biosciences (CLRB) Stock Price, News & Analysis $CLRB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5Gcm5MeURYNEVqdzA4YXBHSThyTkNXMmxTMlZqUmx4UElTbC15NmxKZURkU1h1YzdxeWZfRHZTVm5qN3lNWmxNVVQxYkg1V2Q2TldGUHVFUWthUQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-12T06:12:10+00:00", "published_display": "12 Aug 2016 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 84, "total_relevant": 53, "sentiment_summary": {"positive": 10, "negative": 3, "neutral": 40, "score": 54, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 9.21, "count": 19}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 2.51, "latest_week": "2026-07-17", "one_week_move": -11.0, "four_week_move": -10.0, "twelve_week_move": -9.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.632354, "market_dynamics_buy_signal": false, "relative_strength": -37.035326, "fair_value_gap": -93.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.1006, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-11.0% over one week, -10.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 17}, {"label": "Market source", "count": 8}, {"label": "Quartr", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "Investing.com", "count": 2}, {"label": "TradingView", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Bitget", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 19}, {"label": "Regulatory and legal", "count": 5}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-11.0% over one week, -10.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Cellectar Biosciences (CLRB) Q1 2026 earnings summary"}], "updated_at": "2026-07-24T13:04:57.508759+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}